Pralatrexate (brand name Folotyn) is an anti-cancer therapy. It is the first drug approved as a treatment for patients with relapsed or refractory peripheral T-cell lymphoma or PTCL — a biologically diverse group of aggressive blood cancers that have a poor prognosis.
This page contains content from the copyrighted Wikipedia article "Pralatrexate"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
